Literature DB >> 32679539

Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats.

Yi Zhong1, Yi-Ping Li2, Yong-Qiang Yin2, Bai-Long Hu1, Hong Gao3.   

Abstract

OBJECTIVE: Dexmedetomidine (DEX) was reported to protect heart against ischemic-reperfusion (IR) but the mechanism herein remains elusive. This study aims to explore the mechanism of DEX on pyroptosis induced by myocardial ischemic reperfusion (MIR).
METHODS: MIR rat models were established and injected DEX or miR-29b agomir/antagomir separately. The possible effect of DEX or miR-29b on myocardial cells was assessed according to measurement on creatine kinase-MB (CK-MB), cardiac troponin I (cTnI), interleukin-1β (IL-1β) and interleukin-18 (IL-18), myocardial infarction size, myocardial injury and apoptosis. Western blot determined the expression levels of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein containing CARD (ASC) and cleaved-caspase-1. Hypoxia/reoxygenation (H/R) cell model was established. The lactate dehydrogenase (LDH) content released by myocardial cells was examined. The relation between miR-29b and FoxO3a was confirmed by dual luciferase reporter gene assay. FoxO3a or ARC level was elevated in H/R myocardial cells to detect its effect on pyroptosis.
RESULTS: MIR rat models were successfully established, in which cell pyroptosis was triggered as evidenced by increased expression levels of NLRP3, ASC and cleaved-caspase-1. Rats with DEX precondition had attenuated cell pyroptosis and ameliorated inflammatory response. FoxO3a was a target of miR-29b. MiR-29b agomir or miR-29b antagomir could inhibit or promote the protective effect of DEX on MIR. Overexpression of FoxO3a/ARC axis could suppress myocardial pyroptosis induced by H/R.
CONCLUSION: DEX could ameliorate MIR injury (MIRI) and H/R injury in rats and inhibit H/R induced pyroptosis in myocardial cells via down-regulating miR-29b to activate FoxO3a/ARC axis.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ARC; Dexmedetomidine; FoxO3a; Hypoxia/reoxygenation; Myocardial ischemic reperfusion; Pyroptosis; miR-29b

Mesh:

Substances:

Year:  2020        PMID: 32679539     DOI: 10.1016/j.intimp.2020.106768

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  11 in total

Review 1.  Pyroptosis-Induced Inflammation and Tissue Damage.

Authors:  Yinan Wei; Ling Yang; Ankit Pandeya; Jian Cui; Yan Zhang; Zhenyu Li
Journal:  J Mol Biol       Date:  2021-10-13       Impact factor: 5.469

2.  Dexmedetomidine post-conditioning alleviates myocardial ischemia-reperfusion injury in rats by ferroptosis inhibition via SLC7A11/GPX4 axis activation.

Authors:  Peng Yu; Jing Zhang; Yi Ding; Dandan Chen; Haijian Sun; Fenglai Yuan; Siyuan Li; Xiaozhong Li; Pingping Yang; Linghua Fu; Shuchun Yu; Jiru Zhang
Journal:  Hum Cell       Date:  2022-02-25       Impact factor: 4.374

3.  Dexmedetomidine alleviates cardiomyocyte apoptosis and cardiac dysfunction may be associated with inhibition of RhoA/ROCK pathway in mice with myocardial infarction.

Authors:  Tao Sun; Qian Gong; Ying Wu; Zhiming Shen; Yan Zhang; Shenglin Ge; Jing-Si Duan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-29       Impact factor: 3.000

4.  Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway.

Authors:  Yan Wu; Gaolin Qiu; Hainie Zhang; Leilei Zhu; Gao Cheng; Yiqiao Wang; Yuanhai Li; Weiwei Wu
Journal:  J Cell Mol Med       Date:  2021-10-19       Impact factor: 5.310

5.  Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling.

Authors:  Feng Yun Yang; Lu Zhang; Yan Zheng; He Dong
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

6.  Analysis of the miRNA-mRNA Regulatory Network Reveals the Biomarker Genes in the Progression of Myocardial Ischemic Reperfusion.

Authors:  Nini Li; Qing Chen
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

7.  Dexmedetomidine prevents cardiomyocytes from hypoxia/reoxygenation injury via modulating tetmethylcytosine dioxygenase 1-mediated DNA demethylation of Sirtuin1.

Authors:  Li Wang; Shaowei Wang; Tong Jia; Xiaojia Sun; Zhen Xing; Hui Liu; Jie Yao; Yanlin Chen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 8.  Non-coding RNAs in necroptosis, pyroptosis, and ferroptosis in cardiovascular diseases.

Authors:  Yuxi Cai; Yiwen Zhou; Zhangwang Li; Panpan Xia; Xinxi ChenFu; Ao Shi; Jing Zhang; Peng Yu
Journal:  Front Cardiovasc Med       Date:  2022-08-04

9.  Dexmedetomidine Alleviates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting p75NTR-Mediated Oxidative Stress and Apoptosis.

Authors:  Zhe Wang; Jiali Wu; Zhaolan Hu; Cong Luo; Pengfei Wang; Yanling Zhang; Hui Li
Journal:  Oxid Med Cell Longev       Date:  2020-10-31       Impact factor: 6.543

Review 10.  Impact of the Main Cardiovascular Risk Factors on Plasma Extracellular Vesicles and Their Influence on the Heart's Vulnerability to Ischemia-Reperfusion Injury.

Authors:  Miłosz Majka; Marcin Kleibert; Małgorzata Wojciechowska
Journal:  Cells       Date:  2021-11-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.